oxcarbazepine

(redirected from Oxtellar XR)
Also found in: Medical.
Related to Oxtellar XR: Trokendi XR
Translations

oxcarbazepine

n oxcarbazepina
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
The Company currently markets Trokendi XR (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, and Oxtellar XR (extended-release oxcarbazepine) for the treatment of epilepsy.
After surveying 25 neurologists who currently prescribe Supernus Pharmaceuticals' Oxtellar XR in epilepsy, Piper Jaffray analyst David Amsellem believes the eventual label expansion for the drug as monotherapy for partial seizures, expected before year-end, is unlikely to drive a major uptick in prescription volume growth.
Its top products include Trokendi XR, which treats migraines and epilepsy, and Oxtellar XR, which also treats epilepsy.
M2 PHARMA-June 2, 2016-Supernus awarded sixth US patent for antiepileptic drug Oxtellar XR
Second quarter 2019 product prescriptions for Trokendi XR and Oxtellar XR, as reported by IQVIA, totaled 209,066, a 7.4% increase over the second quarter of 2018.
M2 PHARMA-September 3, 2015-Supernus wins fifth US patent for antiepileptic drug Oxtellar XR
M2 EQUITYBITES-June 23, 2016-Supernus awarded seventh US patent protecting its antiepileptic drug Oxtellar XR
Additionally, Supernus Pharmaceuticals has two marketed products for epilepsy, Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate).
M2 EQUITYBITES-June 2, 2016-Supernus awarded sixth US patent for antiepileptic drug Oxtellar XR
M2 PHARMA-September 5, 2014-Supernus wins fourth US patent for Oxtellar XR for the treatment of epilepsy
M2 PHARMA-January 8, 2014-Supernus Pharmaceuticals Inc wins third US patent for Oxtellar XR for the treatment of epilepsy